Pharmaceutical Business Review

AUGUST 28, 2023

These candidates are being developed to offer better protection, extend the duration in preventing illness and transmission, as compared to the current vaccine technologies. As part of the contract, Allucent will initiate a Phase IIb clinical trial of 10,000 participants under BARDA’s Clinical Studies Network.

Vaccines 52

Vaccines Clinical Pharmacology Immunity Immunization 52

pharmaphorum

AUGUST 16, 2022

Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response. .

Clinical Pharmacology 52

Clinical Pharmacology Immunity Immunization Vaccines 52

pharmaphorum

NOVEMBER 4, 2020

The picture is hardly more promising for vaccines: the number of approaches, difficulty in finding patients in which to carry out pivotal trials, irrelevant choice of endpoints … the outlook is far from promising. The M&S approach should be integrative, from the molecular level to the clinical and population outcomes.

Vaccines 105

Vaccines Clinical Pharmacology Immunity Immunization 105

PharmaShots

MARCH 9, 2023

and medical doctor in clinical pharmacology Other Affiliations: She is a member of the Board of Directors of L’Oréal S.A Designation: Global Head Previous company: Merck Global Vaccines (2 yrs. and Banco Bilbao Vizcaya Argentaria S.A Birthplace: Romana was born and brought up in Toronto.

Clinical Pharmacology 40

Clinical Pharmacology Immunity Immunization Pharmaceutical Companies 40